【Trading Halts】 688496 ST Qingyue 301139 Yuandao Communication
【Trading Resumptions】 002168 ST Huicheng
【Key Corporate Developments】 Two-Day Limit-Up Stock Julong Intelligent: RV Reducer Sales Revenue Proportion Is Small, Impact on Performance Limited Julong Intelligent (002031) issued an announcement regarding abnormal stock price fluctuations, stating that the cumulative deviation of its stock's closing price over the past three trading sessions has exceeded 20%. The company noted that revenue from its RV reducer business constitutes a small proportion of its overall sales and therefore has a limited impact on its financial performance. In 2025, RV reducer revenue was 8.3703 million yuan, accounting for approximately 1% of total annual revenue. Due to influences from downstream industries, the growth trajectory of this business segment remains highly uncertain.
Two-Day Limit-Up Stock Tongding Interconnection: Hainan Corning Serves Solely as Optical Preform Supplier, No Other Cooperation Models Exist Tongding Interconnection (002491) issued an announcement regarding abnormal stock price fluctuations, stating that the cumulative deviation of its stock's closing price over the past three trading sessions has exceeded 20%. The company acknowledged recent heightened market attention on the optical fiber and cable industry. The sustainability of short-term price fluctuations for optical fiber products is uncertain, and their impact on the company's future performance requires comprehensive assessment based on future market conditions and business operations, also carrying uncertainty. The raw material for the company's optical fiber production, optical fiber preforms, are primarily supplied by Corning (Hainan) Optical Communication Co., Ltd. To date, Hainan Corning acts solely as the company's optical preform supplier, with no other forms of cooperation. While current optical fiber market conditions show improvement year-over-year, the company will adjust production capacity release according to market demand. However, resuming and expanding optical fiber production requires consideration of multiple factors, including market prices, supply-demand dynamics, and preform supply capacity. Should any resumption or expansion meet disclosure standards, the company will announce it accordingly. Importantly, the company cautions that changes in the market environment could lead to risks such as declining fiber prices and shifts in supply-demand relationships.
Titan股份: Company's High-End Electronic Fabric Air-Jet Loom Still in R&D Phase, No Sales Revenue Generated Titan股份 (003036) issued an announcement regarding abnormal stock price fluctuations, stating that the cumulative deviation of its stock's closing price over the past three trading sessions has exceeded 20%. The company noted recent significant market interest in the electronic fabric loom concept. Currently, the company's high-end electronic fabric air-jet loom remains in the research and development phase, with no sales revenue generated. Risks include potential delays or failures in the R&D process.
Yuhuan CNC: Company's Products Are Not Applied in the Commercial Aerospace Sector Yuhuan CNC (002903) issued an announcement regarding abnormal stock price fluctuations, stating that the cumulative deviation of its stock's closing price over the past three trading sessions has exceeded 20%. The company's main products are general machine tools such as CNC grinding and broaching equipment; it does not manufacture components for aerospace products. The company's products are not used in the commercial aerospace field, though some products are indirectly applied in the aerospace sector, contributing a minimal proportion of revenue with limited impact on performance. In Q1 2026, revenue from products indirectly used in aerospace was 3.6726 million yuan, accounting for less than 4% of total Q1 revenue. The development of the company's business related to aerospace applications carries significant uncertainty. Investors are advised to exercise caution and be aware of investment risks.
Yifeng Pharmacy: Assistant President Yan Jun Steps Down Yifeng Pharmacy (603939) announced that Yan Jun has resigned from his position as Assistant President due to personal reasons. Following his resignation, he will not hold any other positions within the company.
Fosun Pharma: Subsidiary's Drug HLX05-N Receives FDA Approval for Clinical Trials in the U.S. Fosun Pharma (600196) announced that recently, its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries received approval from the U.S. FDA to conduct a Phase I clinical trial for HLX05-N (recombinant anti-EGFR chimeric monoclonal antibody injection) for the treatment of metastatic colorectal cancer. HLX05-N is a biosimilar of cetuximab injection independently developed by the company and its subsidiaries, intended for the treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma.
Fosun Pharma: Subsidiary's Drug Gains EU Approval for New Indications Fosun Pharma (600196) announced that recently, the following two new indications for Serplulimab Injection (EU trade name: Hetronifly®), independently developed by its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries, were approved by the European Commission: 1. In combination with fluoropyrimidine- and platinum-based chemotherapy, for the first-line treatment of adult patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) with a PD-L1 combined positive score (CPS) ≥5. 2. In combination with carboplatin and pemetrexed, for the first-line treatment of adult patients with EGFR mutation-negative, ALK- or ROS1-negative, unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC). Accordingly, these new indications have been approved in all EU member states as well as Iceland, Liechtenstein, and Norway (which are part of the European Economic Area).
Salubris: JK07's RENEU-HF Clinical Study for Chronic Heart Failure Reports Interim Analysis Data Salubris (002294) announced that recently, interim analysis data was obtained from the RENEU-HF clinical study of its innovative biologic drug JK07 (SAL007) for the treatment of chronic heart failure. Overall, consistent positive signals were observed in patient clinical symptoms and functional indicators. The overall safety profile of JK07 showed a clear correlation with dosage and administration frequency. Based on current data analysis, JK07 can achieve a balance between efficacy and safety in the target patient population, demonstrating a favorable risk-benefit ratio.
【Shareholder Transactions - Increases/Decreases】 *ST Huaxing: Chairman and Core Management Plan to Increase Holdings by 5-6 Million Yuan *ST Huaxing (600340) announced that the company's Chairman and core management plan to increase their holdings of the company's shares through centralized bidding on the Shanghai Stock Exchange system within three months starting May 11, 2026. No specific price range has been set for this increase. The total planned increase amount is no less than 5 million yuan and no more than 6 million yuan.
Yusys Technology: Mingfeng Development Plans to Reduce Holdings by 3% Yusys Technology (300674) announced that shareholder Mingfeng Development Co., Ltd. ("Mingfeng Development"), holding 3.64% of shares, plans to reduce its holdings by 21.0436 million shares (approximately 3.00% of the company's total share capital) within 90 days after three trading days, through block trades and centralized bidding.
*ST Modern: Financial Street Securities Plans to Reduce Holdings by Up to 3% *ST Modern (002656) announced that shareholder Financial Street Holdings Co., Ltd. ("Financial Street Securities"), holding 9.42% of shares, plans to reduce its holdings by no more than 21.3756 million shares (approximately 3.00% of the company's total share capital) through block trades or centralized bidding between June 1 and August 31, 2026.
*ST Dongyi: Tianjin Chenshang Plans to Reduce Holdings by Up to 1.5% *ST Dongyi (002713) announced that shareholder Tianjin Chenshang Consulting Co., Ltd. ("Tianjin Chenshang"), holding 7% of shares, plans to reduce its holdings by no more than 4.757 million shares (no more than 0.5% of total share capital) via centralized竞价 within three months after 15 trading days, and by no more than 9.5141 million shares (no more than 1% of total share capital) via block trades within the same period.
Jingbeifang: Vice Chairman Ding Zhipeng Plans to Reduce Holdings by Up to 0.35% Jingbeifang (002987) announced that Vice Chairman Ding Zhipeng plans to reduce his holdings by no more than 3 million shares (approximately 0.35% of the company's total share capital) through centralized竞价 within three months after 15 trading days.
【Major Contract Awards】 Hanbang Hi-Tech: Subsidiary Signs 2.783 Billion Yuan Contract with Xinghan Tech for High-Performance GPU Equipment Procurement and Integrated Maintenance Services Hanbang Hi-Tech (300449) announced that its wholly-owned subsidiary, Beijing Hanbang Hi-Tech Digital Technology Co., Ltd., signed a "High-Performance GPU Equipment Procurement and Integrated Maintenance Services Contract" with Beijing Qiming Xinghan Technology Co., Ltd. ("Xinghan Tech"). The contract value, including tax, is approximately 2.783 billion yuan (approximately 2.463 billion yuan excluding tax), representing about 1515.13% of the company's audited operating revenue for 2025.
Fengfan股份: Wins Bid for Approximately 86.6412 Million Yuan in State Grid Tender Project Fengfan股份 (601700) announced that on May 7, State Grid Corporation of China published the "Winning Announcement for the Second Open Tender of Installation Materials for State Grid's 2026 Power Transmission and Transformation Projects" and the "Winning Announcement for the First Framework Agreement (Protocol Inventory) Open Tender of Installation Materials for State Grid's 2026 Power Transmission and Transformation Projects." The company was the winning bidder for packages including "Angle Steel Tower Package 3," "Steel Pipe Tower Package 10," "Angle Steel Tower Package 94," and "Angle Steel Tower Package 25" under these announcements. The total winning bid amount is approximately 86.6412 million yuan, representing about 2.91% of the company's audited operating revenue for 2025.
Jinmantu: Wins Bid for Approximately 232 Million Yuan Project Jinmantu (002081) announced that the company recently received a "Winning Bid Notice" from Binzhou Binke Real Estate Co., Ltd. The company has been selected as the winning bidder for the interior finishing supply and construction project of the Weiqiao Guoke (Binzhou) Talent Community, developed by Binzhou Binke Real Estate Co., Ltd. The total winning bid amount is approximately 232 million yuan, accounting for about 1.34% of the company's audited operating revenue for 2025.
Comments